Jean Jacques Bienaime
CIK 1221590 · Chief Executive Officer · last filed 2026-09-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BMRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ASND | Director | 2,000 | $245.87 | $491.7K | $699.3K | 4 | 2026-09-28 |
| KROS | Director | 19,592 | $11.57 | $226.8K | $75.8K | 9 | 2026-08-19 |
| IMNM | Director | 38,915 | $18.56 | $722.3K | $437.4K | 12 | 2026-06-12 |
| INCY | Director | 24,424 | $115.90 | $2.83M | $320.5K | 45 | 2026-06-10 |
| BMRN | Director | 473,892 | $55.78 | $26.43M | -$241.37M | 336 | 2024-05-21 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 1,706 | — | — | $3.9K | 4 | 2014-03-10 |
Recent Filings · Page 7 of 47
465 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-11 | BMRN | Mixed | +317 | -$1.60M | EDGAR |
| 2023-05-10 | BMRN | Notice (144) | −30,000 | -$2.87M | EDGAR |
| 2023-05-09 | BMRN | Notice (144) | −30,000 | -$2.86M | EDGAR |
| 2023-04-12 | BMRN | Mixed | — | -$317.5K | EDGAR |
| 2023-04-10 | BMRN | Mixed | — | -$283.2K | EDGAR |
| 2023-03-17 | BMRN | Mixed | −61,960 | -$9.11M | EDGAR |
| 2023-03-14 | BMRN | Mixed | — | -$548.2K | EDGAR |
| 2023-03-02 | BMRN | Grant (A) | +167,532 | $0 | EDGAR |
| 2023-02-14 | BMRN | Mixed | −100 | -$882.5K | EDGAR |
| 2023-01-18 | BMRN | Mixed | — | -$881.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.